Gene Therapy Startups

ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.

7 investors

Kopra Bio develops cancer immunotherapy technology that converts cancer cells into biofactories to produce their own destruction. The company operates in the biotech and cancer treatment space.

6 investors

64x develops infrastructure and manufacturing systems for next-generation medicines, focusing on genetic engineering, cell line development, and computational biology to enable scalability of advanced therapies.

5 investors

FinalDose develops a programmable DNA-targeting molecule designed to recognize and destroy cells carrying specific genetic sequences, with initial applications in oncology across cancer types.

4 investors

Nephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.

3 investors

Rejuvenation develops proprietary mRNA and lipid nanoparticle technology to safely lengthen telomeres in human cells, targeting cellular aging and diseases caused by short telomeres including pulmonary fibrosis, liver disease, and bone marrow failure.

3 investors

Modulari-T develops proprietary cell therapy technologies, including the MARC receptor and MoVe platform, based on primary research into immune system architecture. The company serves the cell therapy and immunotherapy market.

2 investors

Nuntius develops programmable nanocarriers for drug delivery that can target tissues beyond the liver and utilize machine learning to optimize carrier performance. The company serves pharmaceutical and biotech organizations developing targeted therapeutics.

2 investors

Sixfold develops RNA delivery technology for the biotech industry. The company was founded by an oncologist and plant scientist and focuses on advancing RNA-based therapeutic approaches through proprietary delivery methods.

2 investors

Uncommon Therapeutics uses advanced technologies to develop drugs targeting rare genetic diseases, starting with Rett Syndrome, a neurodevelopmental disorder affecting approximately 1 in 10,000 girls. The company combines disease expertise with efficient drug development to advance therapeutics from discovery to clinical application.

2 investors

Andson Biotech develops analytical tools for the analysis of biotherapeutics, aimed at supporting the discovery and development of biologic drugs.

1 investor

Indee Labs develops Hydropore™, a non-viral microfluidic technology for delivering molecules, nucleic acids, proteins, and gene-editing complexes into immune cells for engineered cell therapy research and manufacturing. The platform enables rapid production of high-quality T-cell immunotherapies and other cell therapies with preserved cell function.

1 investor

Perception Biosystems develops automated manufacturing systems for gene therapy production, aiming to reduce the time and cost of producing therapies for rare disease clinical trials.

1 investor

WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

1 investor